Case Report
Cardiac Involvement by Human Herpesvirus 8-Positive Diffuse Large B-Cell Lymphoma: An Unusual Presentation in a Patient with Human Immunodeficiency Virus

Elena M. Fenu, Michael W. Beaty, Tiffany E. O’Neill, and Stacey S. O’Neill

Atrium Wake Forest Baptist Health, Department of Pathology, Winston-Salem, NC, USA
Correspondence should be addressed to Elena M. Fenu; efenu@wakehealth.edu

Received 24 September 2021; Revised 13 December 2021; Accepted 26 December 2021; Published 17 January 2022

Academic Editor: Samir Sami Amr

Copyright © 2022 Elena M. Fenu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Human immunodeficiency virus (HIV) infection predisposes patients to the development of lymphomas, both due to immune suppression and coinfection with viruses with oncogenic potential. Coinfection with human herpesvirus 8 (HHV8) in particular has been associated with the development of aggressive lymphomas, including primary effusion lymphoma and diffuse large B-cell lymphoma (DLBCL). Herein, we report an unusual case of HHV8-positive DLBCL with extensive cardiac involvement which was diagnosed at autopsy in a patient with long-standing untreated HIV infection.

1. Introduction

Patients with human immunodeficiency virus (HIV) infection are at increased risk for infection and malignancy due to impaired cellular immunity. Prior to the advent of modern antiretroviral therapy (ART), HIV-positive individuals had a risk of acquiring non-Hodgkin lymphoma that was 25- to 150-times higher than that of the general population [1]. Although treatment with ART has greatly improved life expectancy and decreased cancer risk, lymphoma remains a leading cause of mortality in individuals with HIV infection [2].

Due to immune suppression and immune dysregulation, HIV-infected individuals are susceptible to coinfection with other viruses including those with oncogenic potential such as human herpesvirus 8 (HHV8) and Epstein-Barr virus (EBV). Such viral-associated lymphoproliferative disorders include multicentric Castleman disease, primary effusion lymphoma (PEL), and HHV8-positive diffuse large B-cell lymphoma (DLBCL). Herein, we report a case of an unusual presentation of a rare and aggressive lymphoma in a young patient due to coinfection with HIV and HHV8.

A 38-year-old male with a history of known, but untreated, HIV for approximately 9 years, was found face down deceased at his residence when a welfare check was conducted. Per his significant other, he had multiple episodes of fainting on the day of his death. An autopsy was performed.

At autopsy, the heart was grossly abnormal, with increased size (900 grams) and a thickened, red-pink gelatinous epicardial surface (Figure 1). Numerous adhesions between the pericardial and epicardial surfaces were present. Of note, there was no measurable pericardial effusion. Focal firmness and tan discoloration of the right atrium were evident, without overt increase in myocardial wall thickness. Heart valves were unremarkable, and coronary arteries were widely patent. There was diffuse lymphadenopathy, including prominent intraparenchymal pulmonary, mediastinal, perigastric, and peripancreatic lymph nodes. Splenomegaly (710 grams) was present. No skin lesions or other significant gross abnormalities were identified. No pleural effusion or ascites was detected.

On microscopic examination, sections of the right atrium of the heart demonstrated transmural infiltration by large pleomorphic cells with a plasmablastic appearance with prominent nucleoli and high nuclear to cytoplasmic ratio. Abundant mitoses were present. There was extensive disruption of normal cardiac architecture and associated myocyte injury (Figure 2). The right and left ventricles were
uninvolved. Sections of the thickened epicardium showed chronic pericarditis without an atypical large lymphoid cell infiltrate. Representative sections of peripancreatic and perigastric lymph nodes showed sheets of similar-appearing neoplastic cells extending into adipose tissue. Sections of uninvolved pulmonary lymph nodes were significant for a prominent sinusoidal and capsular expansion of small mature plasma cells. The spleen showed increased plasma cells around central arterioles, but was negative for infiltration by the large pleomorphic lymphoid cells.

By immunohistochemistry, the large pleomorphic cells within the right atrium stained positive for CD45 and MUM1 and were negative for CD138, CD79a, PAX5, CD19, BCL6, MYC, CD56, and CD2 (Figure 3). A subset of the cells stained dimly positive for CD20 and CD30. Immunohistochemistry for HHV8-associated latent protein was strongly and diffusely positive in the neoplastic cells. In situ hybridization for EBV-encoded small RNA (EBER) was negative. Light chain in situ hybridization showed variable weak staining for kappa light chains in the large neoplastic cells; lambda light chain was negative. Of note, flow cytometric analysis was not possible due to lack of fresh tissue procured at the time of autopsy. Sections of pericardium confirmed the absence of a significant HHV8-positive large cell infiltrate (Figure 4), supporting a reactive pericarditis.

Together, the findings were indicative of an aggressive HHV8-associated lymphoproliferative disorder, with the leading differential diagnoses including HHV8-positive DLBCL and extracavitary variant of PEL. These two entities can show overlapping morphologic and immunophenotypic features, and distinguishing them can be challenging [3]. In addition to HHV8, PEL typically expresses CD45, CD138, CD38, MUM1, CD30, and EMA, but lacks B-cell antigens CD19, CD20, and CD79a. Surface and cytoplasmic light chain expression is typically absent. Of note, the extracavitary variant of PEL can show some B-cell antigen and/or immunoglobulin expression. Importantly, PEL in HIV-positive patients is invariably positive for EBV [4]. In HHV8-positive DLBCL, the neoplastic cells are typically positive for MUM1 with variable expression of CD45 and B-cell markers CD20, PAX5, and without expression of CD138, CD79a, or EBER. Restricted light chain expression, frequently lambda, is often seen. In the current case, the lack of EBV and CD138 in conjunction with the presence of diffuse lymphadenopathy favors the diagnosis of HHV8-positive DLBCL, not otherwise specified (NOS) in this patient with long-standing untreated HIV infection. The extensive cardiac involvement was deemed to have directly caused cardiac arrest and death.

Cardiac involvement by lymphoma is unusual. A review of case reports published between 2009 and 2019 found only 158 cases of lymphoma involving the heart, of which 101 were defined as primary cardiac lymphomas (lymphomas with only cardiac involvement) [5]. In this review, the most common lymphoma to involve the heart was DLBCL (88 out of 101 cases), and the right atrium and right ventricle were most frequently involved [6]. Lymphomas may also involve the heart after becoming widely disseminated [7]. Cardiac involvement by nonprimary disease is rare, and a population series reviewing over 12,000 autopsies found heart metastases in 1.23% of cases, of which the most commonly encountered were lung, lymphoma, breast, leukemia, stomach, melanoma, liver, and

Figure 1: A photograph of a cross-section of the heart with thickened and gelatinous-appearing epicardium.

Figure 2: Histologic sections of the heart showed infiltration by mitotically active, pleomorphic cells, with associated myonecrosis. (a) and (b)H&E (hematoxylin and eosin) at 10× and 40× magnification, respectively.
colon [8]. In cases of cardiac involvement by lymphoma, common presenting symptoms include dyspnea, chest pain, and syncope. Arrhythmias, signs of heart failure, and cardiac tamponade have also been reported [9]. The disease has a high mortality, and treatment typically involves chemotherapy or chemotherapy combined with surgery in patients experiencing hemodynamic compromise [10].
HHV8-positive DLBCL is a rare lymphoma with an incidence of only ~0.1% and is usually associated with HIV infection. The presence of HHV8-positive multicentric Castleman disease (MCD) increases the risk of HHV8-positive DLBCL by approximately 15-fold [11]. It is proposed that increased large plasmablastic-like cells arise in MCD and expansion leads to DLBCL. Of note, in the current case, sampled uninvolved pulmonary lymph node showed a sinusoidal and capsular plasma cell expansion with polytypic light chain expression by kappa/lambda in situ hybridization and scattered HHV8 positive cells, but no definitive demonstration of MCD in the limited lymph node sampling. HHV8-positive DLBCL is an aggressive disease, often involving lymph nodes or spleen, but also may involve the peripheral blood and bone marrow, or disseminate to other visceral organs including the liver, lungs, and gastrointestinal tract. Patients are typically male, and the median age is 47 (with a range of 39-66). [12] Morphologically, the cells often are characterized by a plasmablastic appearance with multiple, eccentrically placed nucleoli. In contrast to PEL, HHV8-positive DLBCL presents as a serous effusion without a distinct tumor mass [15]. Morphologically, the cells have an immunoblastic to plasmablastic appearance with prominent nucleoli and abundant basophilic cytoplasm. They typically express plasma cell-related markers without B-cell antigen expression and are characteristically dual positive for HHV8 and EBV, particularly in the setting of HIV infection. However, the neoplastic cells in the extracavitary variant can show less plasma cell marker expression with increased B-cell antigen expression. In rare cases, PEL may involve the heart, with one case report in the literature describing PEL involving the atria in a 31-year old patient with HIV also with a concurrent large pericardial effusion [16]. In contrast, PBL typically presents with an extranodal mass, most often in the oral cavity or gastrointestinal tract. The neoplastic cells show a plasma cell immunophenotype, with expression of CD138, CD38, MUM1, variable CD79a, and restricted cytoplasmic light chains. EBV is positive, particularly when associated with HIV infection, and HHV8 is consistently absent. Overall, these aggressive lymphomas including HHV8-positive DLBCL, PEL, and PBL can show overlapping features, but the presence or absence of HHV8 and EBV in addition to the relative expression of plasma cell markers or B-cell antigens is helpful in distinguishing between these entities [3, 4] (Table 1).

Herein, we present an unusual case of cardiac involvement by HHV8-associated aggressive lymphoma in a male with long-standing untreated HIV infection diagnosed at autopsy. The pattern of disease, including disseminated lymphadenopathy and lack of effusions, and phenotype with lack of CD138 expression and EBV supports the diagnosis of

| CD45 | CD20 | CD19 | CD79a | MUM1 | CD138 | Ig | EBV | HHV8 |
|------|------|------|-------|------|-------|----|-----|------|
| +/−  | +/−  | +/−  | −     | +    | −     | +  | −   | +    |
| Primary effusion lymphoma | +    | −    | −     | −    | +    | −  | −   | +    |
| Plasmablastic lymphoma    | −    | −    | −     | +/−  | +    | +  | +   | (c)  |
|                           |      |      |       | (c/s)|      |     |     |      |

Ig indicates immunoglobulin expression, with c/s indicating cytoplasmic or surface. EBV indicated Epstein-Barr virus in situ hybridization.
HHV8-positive DLBCL. Untreated HIV has become much less common with the widespread adoption of ART, however, HIV viremia and reduced CD4-T cell counts predispose to rare and aggressive hematolymphoid malignancies.

Data Availability

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Consent

No identifying patient information is given within the article.

Conflicts of Interest

The authors have no relevant financial or nonfinancial interests to disclose.

Authors’ Contributions

All authors contributed to the pathologic assessment of this case. The first draft of the manuscript was written by Elena Fenu, and all authors commented on the manuscript. All authors read and approved the final manuscript.

References

[1] T. M. Gibson, L. M. Morton, M. S. Shiels, C. A. Clarke, and E. A. Engels, “Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study,” AIDS, vol. 28, no. 15, pp. 2313–2318, 2014.

[2] C. J. Smith, L. Ryom, R. Weber et al., ”D: A:D study group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A:D): a multicohort collaboration,” Lancet, vol. 384, no. 9939, pp. 241–248, 2014.

[3] F. Vega, R. N. Miranda, and L. J. Medeiros, ”KSHV/HHV8-positive large B-cell lymphomas and associated diseases: a heterogeneous group of lymphoproliferative processes with significant clinicopathological overlap,” Modern Pathology, vol. 33, no. 1, pp. 18–28, 2020.

[4] J. Zhou and M. Nassiri, ”Lymphoproliferative neoplasms with plasmablastic morphology: an overview and diagnostic approach,” Archives of Pathology & Laboratory Medicine, 2021.

[5] H. Chen, S. Qian, P. Shi, L. Liu, and F. Yang, ”A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 2019,” International Journal of Hematology, vol. 112, no. 1, pp. 65–73, 2020.

[6] A. Petrich, S. I. Cho, and H. Billett, ”Primary cardiac lymphoma,” Cancer, vol. 117, no. 3, pp. 581–589, 2011.

[7] D. O’Mahony, R. L. Peikarz, W. P. Bandettini, A. E. Arai, W. H. Wilson, and S. E. Bates, ”Cardiac involvement with lymphoma: a review of the literature,” Clinical Lymphoma and Myeloma, vol. 8, no. 4, pp. 249–252, 2008.

[8] K. P. Abraham, V. Reddy, and P. Gattuso, ”Neoplasms metastatic to the heart: review of 3314 consecutive autopsies,” American Journal of Cardiovascular Pathology, vol. 3, pp. 195–198, 1990.

[9] H. Ikeda, S. Nakamura, H. Nishimaki et al., ”Primary lymphoma of the heart: case report and literature review,” Pathology International, vol. 54, no. 3, pp. 187–195, 2004.

[10] K. Jonavicius, K. Salcius, R. Meskauskas, N. Valeviciene, V. Tarutis, and V. Sirvydis, ”Primary cardiac lymphoma: two cases and a review of literature,” Journal of Cardiothoracic Surgery, vol. 30, p. 138, 2015.

[11] E. Oksenhendler, E. Boulanger, L. Galicier et al., ”High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease,” Blood, vol. 99, pp. 2331–2336, 2002.

[12] L. Qunaj, J. J. Castillo, and A. J. Olszewski, ”Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base,” Leukemia & Lymphoma, vol. 59, pp. 1375–1383, 2018.

[13] N. Suksawai, K. Lyapichev, J. D. Khoury, and L. J. Medeiros, ”Diffuse large B-cell lymphoma variants: an update,” Pathology, vol. 52, no. 1, pp. 53–67, 2020.

[14] C. M. Schneider, A. Buiatti, K. Schwamborn, and R. J. Dirschinger, ”Diagnosis of a rare cardiac human herpesvirus-8 positive B-cell lymphoma manifestation: a case report of a transoesophageal echocardiography-guided trans-septal catheter biopsy,” European Heart Journal Case Reports, vol. 2, no. 2, 2018.

[15] E. Campo, N. L. Harris, E. S. Jaffe et al., ”(2017) WHO Classification of Haematopoietic and Lymphoid Tissues (International Agency for Research on Cancer, Lyon), International Agency for Research on Cancer (IARC), Lyon, France, 4th ed. edition, 2017.

[16] I. Marcic, S. Washington, A. Schwartz, V. Anandan, and D. S. Karcher, ”Human herpesvirus-8-positive body cavity-based lymphoma involving the atria of the heart: a case report,” Cardiovascular Pathology, vol. 11, no. 4, pp. 244–247, 2002.